Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries

作者：Milena A. Gianfrancesco, Kimme Leanne Hyrich, Laure Gossec, Anja Strangfeld, Loreto Carmona, Elsa Frãzao Mateus, Paul Sufka, Rebecca Grainger, Zachary Scott Wallace, Suleman Bhana, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Wendy Costello, Philip C. Robinson, Pedro Machado, Jinoos Yazdany · 发表于：The Lancet Rheumatology · 年份：2020 · DOI：10.1016/s2665-9913(20)30095-3 · 被引用次数：220 · 研究领域：Rheumatoid Arthritis Research and Therapies、COVID-19 Clinical Research Studies、Autoimmune and Inflammatory Disorders Research

Individuals with inflammatory rheumatic disease require special consideration with regard to coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many of these individuals are considered at-risk for serious infections due to their immunocompromised state resulting from their underlying immune conditions and use of targeted immune-modulating therapies such as biologics.1–4 However, some disease-modifying drugs commonly used to treat rheumatic diseases, such as hydroxychloroquine, are being investigated as potential therapies for COVID-19.